# CareDx, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [CareDx, Inc.](/companies/cdna.md) (CIK 1217234)
- Form: 10-Q
- Filed: 2018-11-08
- Accepted by EDGAR: Nov 8, 2018, 16:52 ET
- Period: 2018-09-30
- Accession: 0001564590-18-028612
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1217234/000156459018028612/cdna-10q_20180930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1217234/000156459018028612/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $21.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $53.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $3.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $10.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | −$13.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | −$290.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | −$1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | −$20.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | −$43.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.54 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | −$1.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.54 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | −$1.26 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 37,154,293 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 34,134,138 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$6.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $1.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2018-01-01 to 2018-09-30 | $698.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-09-30 | $26.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $41.9m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $91.4m | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $15.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $47.1m | us-gaap:Liabilities |
| Long-term debt | at 2018-09-30 | $13.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-09-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-09-30 | $44.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 69,501 characters.

*The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission, or the SEC, on March 22, 2018.*

### SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and the negative and plural forms of these words and similar expressions are intended to identify forward-looking statements.

These forward-looking statements may include, but are not limited to, statements concerning the following:

- our ability to generate revenue from sales of AlloMap, AlloSure and future testing services, if any, and our ability to increase the commercial success of these testing services;
- our ability to generate revenue from sales of Olerup SSP, Olerup SBT, Olerup QTYPE, TruSight HLA, and future products, if any, and our ability to increase the commercial success of these products;
- our ability to generate revenue from the license and commercialization agreement with Illumina, Inc.;
- our plans and ability to develop and commercialize new solutions for the surveillance of heart, kidney, and other solid organ transplant recipients; our plans and ability to continue updating our products, services and technology to maintain our leading position in the surveillance market for solid organ transplants;
- our plans and ability to continue updating our sequence specific primer products and technology to maintain our leading position in the SSP market;
- our plans and ability to develop, commercialize, and/or distribute new gene expression, qPCR, cell free DNA and Next Generation Sequencing technology applications for transplantation;
- our ability to obtain additional financing on terms favorable to us, or at all;
- our ability to remain eligible to use Registration Statements on Form S-3 for capital-raising transactions;
- our ability to obtain, maintain and expand reimbursement coverage from payers for AlloMap, AlloSure and other future testing services, if any;
- the outcome or success of our clinical trial collaborations and registry studies;
- our dependence on certain of our suppliers, service providers, and other distribution partners;
- our compliance with federal, state and foreign regulatory requirements;
- the favorable review of our testing services and product offerings, and our future solutions, if any, in peer-reviewed publications;
- our ability to protect and enforce our intellectual property rights, our strategies regarding filing additional patent applications to strengthen our intellectual property rights, and our ability to defend against intellectual property claims that may be brought against us;
- our anticipated cash needs and our anticipated uses of our funds, including our estimates regarding operating expenses and capital requirements;
- our ability to meet our obligations under our equity financing agreements and debt agreements;
- anticipated trends and challenges in our business and the markets in which we operate;
- disruptions to our business, including disruptions at our laboratories and manufacturing facilities;
- our ability to retain key members of our management team;
- our ability to make successful acquisitions or investments and to manage the integration of such acquisitions or investments;
- our ability to successfully defend against or settle any litigation brought against us or other legal matters or disputes;
- our ability to expand internationally; and
- our ability to comply with the requirements of being a public company.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled “Risk Factors” in this Quarterly Report on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. We qualify all forward-looking statements by these cautionary statements.

### Overview and Recent Highlights

We are a global transplant diagnostics company with product and service offerings along the pre- and post-transplant continuum. We focus on discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients.

### Testing Services

### AlloMap

Our first commercialized testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection. Since 2008, we have sought to expand the adoption and utilization of our AlloMap solution through ongoing studies to substantiate the clinical utility and actionability of AlloMap, secure positive reimbursement decisions for AlloMap from large private and public payers, develop and enhance our relationships with key members of the transplant community, including opinion leaders at major transplant centers, and explore opportunities and technologies for the development of additional solutions for post-transplant surveillance. We believe the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, we believe AlloMap can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. In 2008, AlloMap received 510(k) clearance from the U.S. Food and Drug Administration, or FDA, for marketing and sale as a test to aid in the identification of recipients with a low probability of moderate or severe acute cellular rejection.

AlloMap has received positive coverage decisions for reimbursement from Medicare. The 2018 reimbursement rate for AlloMap is $3,240, which represents a 14% increase over the 2017 reimbursement rate. AlloMap has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers, including Aetna, Anthem, Cigna, Health Care Services Corporation (HCSC), Humana, Kaiser Foundation Health Plan, Inc., and TRICARE.

We have also successfully completed a number of landmark clinical trials in the transplant field demonstrating the clinical utility of AlloMap for surveillance of heart transplant recipients. We initially established the analytical and clinical validity of AlloMap on the basis of our Cardiac Allograft Rejection Gene Expression Observational (Deng, M. et al., Am J Transplantation 2006), or CARGO, study, which was published in the *American Journal of Transplantation*. A subsequent clinical utility trial, Invasive Monitoring

Attenuation through Gene Expression (Pham MX et al., N. Eng. J. Med., 2010), or IMAGE, published in The New England Journal of Medicine, demonstrated that clinical outcomes in recipients managed with AlloMap surveillance were equivalent (non-inferior) to outcomes in recipients managed with biopsies. The results of our clinical trials have also been presented at major medical society congresses.

During the first nine months of 2018, there were 12,059 AlloMap patient test results provided to 131 of the approximately 137 heart transplant management centers in the United States.

### AlloSure

AlloSure, our recently launched commercial transplant surveillance solution, applies proprietary next generation sequencing technology to measure donor-derived cell free DNA, or dd-cfDNA in the blood stream emanating from the donor kidney or heart. We believe AlloSure may help clinicians determine rejection-specific activity manifested as cell damage in the transplanted heart, kidney and other solid organs, irrespective of the type of organ transplanted. We also believe the use of AlloSure, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a kidney transplant. In particular, we believe AlloSure can improve patient care by helping healthcare providers to reduce the use of invasive biopsies and determine the appropriate dosage levels of immunosuppressants. Effective October 9, 2017, AlloSure became available for commercial testing with Medicare coverage and reimbursement. The Medicare reimbursement rate for AlloSure is $2,841. AlloSure has also received payment from private payers on a case-by-case basis, but no positive coverage decisions have been made.

Prior to the commercialization of AlloSure, we generated a strong body of clinical evidence. In late 2015, we announced the completion of analytical validation of AlloSure. A report describing the analytical validation of AlloSure including clinical validation detailing the quality, reality, and consistency of analytical results information for heart transplant, appeared in the November 2016 issue of The Journal of Molecular Diagnostics. The Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients, or DART, trial, sponsored by us, was conducted between April 2015 and January 2018. DART is a 14 center observational study of kidney transplant recipients where blood specimens are drawn periodically after transplant during follow up visits and also after treatment for acute rejection. By the time of completion of the first analysis, 384 patients were followed in DART for up to 24 months. The results demonstrated that increased levels of dd-cfDNA, determined by the AlloSure assay, discriminated active rejection of a kidney transplant more effectively than serum creatinine values. In collaboration with clinical investigators, we published these findings in the scientific peer-reviewed Journal of the American Society of Nephrology and the Journal Applied Laboratory Medicine in March 2017. A total of 2,109 patient visits had been accrued in DART by January 2018; we plan to analyze and report on additional findings from this dataset in 2018 and into the future.

In 2018, we initiated the Kidney Allograft Outcomes AlloSure Registry, or K-OAR study, to develop further data on the clinical utility of AlloSure for surveillance of kidney transplant recipients. As of September 30, 2018, 40 centers have been initiated as K-OAR study sites.

During the first nine months of 2018, there were 7,059 AlloSure patient test results provided. Since launch, AlloSure has been ordered by 96 kidney transplant centers in the United States.

### HeartCare

In September, 2018, we initiated the Surveillance HeartCare® Outcomes Registry (“SHORE”). SHORE is a prospective, multi-center, observational, registry of patients receiving HeartCare for surveillance.

HeartCare combines the gene expression profiling technology of AlloMap with the dd-cfDNA analysis of AlloSure-Heart in one surveillance solution. An approach to surveillance using HeartCare provides information from two complementary measures: (i) AlloMap – a measure of immune activity, and (ii) AlloSure-Heart® – monitors graft injury. HeartCare provides robust information about distinct biological processes, such as immune quiescence, active injury, Acute Cellular Rejection (“ACR”) and Antibody Mediated Rejection (“AMR”).

### Products

We develop, manufacture, market and sell products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is used to type Human Leukocyte Antigen, or HLA alleles, based on the sequence specific primer, or SSP technology. Olerup SBTTM is a complete product range for sequence-based typing of HLA alleles. Olerup QTYPE enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction, or PCR, methodology. QTYPE received CE mark certification on April 10, 2018.

On May 4, 2018, we entered into a License and Commercialization Agreement (the “License Agreement”) with Illumina, Inc. (“Illumina”), which provides us with worldwide distribution, development and commercialization rights to Illumina’s next generation sequencing (“NGS”) product line for use in transplantation diagnostic testing.

As a result, on June 1, 2018, we became the exclusive worldwide distributor of Illumina’s TruSight HLA product line. In addition, we were granted the exclusive right to develop and commercialize other NGS product lines for use in the field of bone marrow and solid organ transplantation diagnostic testing.

### Recent Highlights

- Continued the acceleration of AlloSure penetration
- In the twelve months since launch, 96 U.S. transplant centers have provided AlloSure testing to over 4,000 patients, representing approximately 2% of all U.S. living kidney transplant patients. The number of standing order patients has increased to 2,736, cumulatively
- Continued progress in AlloSure Registry (K-OAR) enrollment, with 40 centers initiated and 480 patients enrolled as of September 30, 2018
- Achieved total revenue of $21.2 million for the third quarter of 2018, increasing 74% year-over-year
- Testing services revenue of $16.8 million, with 3,708 AlloSure and 4,080 AlloMap patient results provided
- Product revenue of $4.2 million
- Broadened testing services and product offerings
- Launched the Surveillance HeartCare® Outcomes Registry (SHORE) during the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA)
- Profiled the new AlloSeq suite of next generation sequencing based transplant laboratory products, to be launched in 2019, at the American Society of Histocompatability and Immunogenetics (ASHI)

### Financial Operations Overview

#### Revenue

We derive our revenue from testing services, products sales and license and other revenues. On January 1, 2018, we adopted the new revenue accounting standard *Revenue from Contracts with Customers (Topic 606)*, or ASC 606, using the modified retrospective method. The adoption of ASC 606 resulted in a one-time adjustment of $2.9 million to accounts receivable and retained earnings. This adjustment reflects the estimated payments to be received for tests where the result had been delivered at December 31, 2017, but the associated revenue had not been recognized by December 31, 2017, because payment had not been received. Under the new accounting standard, revenue is recorded considering a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation. As of September 30, 2018, we had received payments of $3.2 million for tests where the results had been delivered at December 31, 2017, but associated revenue had not been recognized by December 31, 2017. Payments received in excess of the $2.9 million accounts receivable adjustment recorded on January 1, 2018 were recognized in testing services revenue in the period of collection.

#### Testing Services Revenue

Our testing revenue is derived from AlloMap and AlloSure tests, which represented 80% and 78% of our total revenues for the three and nine months ended September 30, 2018, respectively, and 67% and 68% of our total revenues for the three and nine months ended September 30, 2017, respectively. We currently market AlloMap and AlloSure in the U.S. to healthcare providers through our direct sales force that targets transplant centers and their physicians, coordinators and nurse practitioners. The healthcare providers that order the tests and on whose behalf we provide our testing services are generally not responsible for the payment of these services. Amounts received by us vary from payer to payer based on each payer’s internal coverage practices and policies. We generally bill third-party payers upon delivery of an AlloMap or AlloSure test result report to the healthcare provider. As such, we take the assignment of benefits and the risk of collection from the third-party payer and individual patients.

#### Product Revenue

Our product revenue is derived primarily from sales of Olerup and TruSight branded products. Product revenue represented 20% and 21% of total revenue for the three and nine months ended September 30, 2018, respectively, and 32% and 30% of total revenue for the three and nine months ended September 30, 2017, respectively. Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied, which is generally upon the product shipment.

#### License and Other Revenue

License agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. Our performance obligations under the license agreements may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees. We make judgments that affect the periods over which we recognize revenue. We review our estimated periods of performance based on the progress under each arrangement and account for the impact of any change in estimated revenues.

We did not recognize any revenue connected with milestones during the three or nine months ended September 30, 2018 or 2017.

#### Cost of Testing Services

Cost of testing services reflects the aggregate costs incurred in delivering our testing services. The components of cost of testing services are materials and service costs, direct labor costs, stock-based compensation expense, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation, utilities and royalties. Prior to adoption of the new revenue guidance, we recorded cost of testing services associated with performing tests (except royalties) in the period when tests were performed without consideration of whether revenue was recognized in the same period. With the adoption of the new revenue standard on January 1, 2018, revenue and cost of testing services for tests performed are recognized in the same period. Royalties for licensed technology, calculated as a percentage of testing services revenues, are recorded as license fees in cost of testing at the time the testing services revenues are recognized.

#### Cost of Product

Cost of product reflects the aggregate costs incurred in delivering our products to customers. The components of cost of product are material costs, manufacturing and kit assembly costs, direct labor costs, including equipment and infrastructure expenses associated with preparing kitted products for shipment, shipping, distributorship agreements and allocated overhead, including rent, information technology, equipment depreciation and utilities. Cost of product also includes amortization of acquired developed technology and adjustments to inventory values, including write-down of impaired, slow moving or obsolete inventory.

#### Research and Development Expenses

Research and development expenses, including clinical operations, represent costs incurred to develop diagnostic products and services, high quality evidence to support use of our tests, as well as continued efforts related to improving our existing product and service lines. These expenses include payroll and related expenses, consulting expenses, laboratory supplies, clinical studies and certain allocated expenses as well as amounts incurred under certain collaborative agreements. Research and development costs are expensed as incurred. We record accruals for estimated study costs comprised of work performed by contract research organizations under contract terms.

#### Sales and Marketing Expenses

Sales and marketing expenses represent costs incurred to sell, promote and increase awareness of our existing products and services to transplant centers and hospital laboratories. These efforts also include education of patients, clinicians, payers, and other relevant decision makers. Sales and marketing expenses include payroll and related expenses, educational and promotional expenses, and infrastructure expenses, including allocated facility and overhead costs. Compensation related to sales and marketing includes annual salaries and eligibility for periodic bonuses based on the achievement of predetermined sales goals or other management objectives.

#### General and Administrative Expenses

General and administrative expenses include costs for our executive, finance, accounting and human resources functions. Costs consist primarily of payroll and related expenses, professional service fees related to audit and accounting, certain financing transaction expenses, and legal and other contract and administrative services. We will continue to incur expenses as a result of operating as a public company.

#### Goodwill Impairment

We test goodwill and indefinite-lived intangibles for impairment at least annually and more frequently if impairment indicators are present. In the three months ended March 31, 2017, we determined that the decrease in our market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017. We identified an impairment of $2.0 million related to goodwill.

No goodwill impairment indicators were present in the three or nine months ended September 30, 2018 and therefore no impairment was recorded.

#### Change in Estimated Fair Value of Contingent Consideration

We revalue our contingent consideration obligation liability in connection with our acquisition of IMX in 2014 at each reporting period. Changes in the fair value of our contingent consideration obligation are recognized as a component of operating expense within our condensed consolidated statements of operations. We achieved the contingent consideration obligation milestone of 2,500 commercial tests and issued 227,845 shares in the three month period ended June 30, 2018. There is no contingent consideration outstanding as of September 30, 2018.

#### Interest Expense

Interest expense is associated with borrowings under our loan agreements and also includes debt discount amortization.

#### Other Expense

Other expense includes gains and losses on foreign currency transactions, on debt extinguishment, and other miscellaneous expenses. During the nine months ended September 30, 2018, we recorded $2.8 million loss on the conversion of the JGB Debt as the difference between the value of the shares of common stock issued on the days of conversion and the amount of principal debt converted on those days, net of the allocated debt discount and derivative liability balances.

#### Change in Estimated Fair Value of Common Stock Warrant Liability and Derivative Liability

Common stock warrants issued in connection with our debt and equity financings are considered freestanding financial instruments and are analyzed as to whether they meet equity or liability classification in accordance with United States generally accepted accounting principles, or US GAAP. Warrants that meet liability classification are re-measured at each period end with changes in fair value recorded in our condensed consolidated statements of operations until these warrants are exercised or expire. On January 1, 2018, we adopted Accounting Standards Update No. 2017-11, *Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral of Mandatorily Redeemable Financial Instruments of Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception* and this resulted in the liability balance for our warrants issued to JGB being reclassified to equity on the date of adoption.

The JGB Debt included certain embedded derivatives that required bifurcation, including settlement and penalty provisions. The embedded derivative was remeasured at each reporting period with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability in the condensed consolidated statements of operations. As of March 27, 2018, the JGB Debt had fully converted to shares of our common stock. On April 17, 2018, we entered into a credit agreement with perceptive Credit Holdings II, LP, or Perceptive, for an initial term loan of $15.0 million, or the Perceptive Credit Agreement, which included an embedded derivative that required bifurcation related to early repayment provision. We record changes in the fair value of the derivative liabilities in the change in estimated value of common stock warrant liability and derivative liability in our condensed consolidated statements of operations.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are described in Note 2 of the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information. Some of these accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe that the following critical accounting policies reflect the more significant estimates and assumptions used in the preparation of our financial statements. We believe the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our Condensed Consolidated Financial Statements:

- Revenue recognition – estimation of variable consideration
- Determination of the accruals for clinical studies,
- Inventory valuation
- Valuation of common stock warrant liability
- Valuation of embedded derivative liability
- Valuation and impairment of goodwill, intangible assets and other long-lived assets;
- Goodwill and acquired intangible assets
- Share-based compensation; and
- Accounting for income taxes.

There were no material changes in the matters for which we make critical accounting estimates in the preparation of our Condensed Consolidated Financial Statements during the three and nine months ended September 30, 2018 as compared to those disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our annual report on Form 10-K for the year ended December 31, 2017, except as discussed in Note 2, Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements in this quarterly report.

### Recently Issued Accounting Standards

Refer to Note 2, Summary of Significant Accounting Policies - Recent Accounting Pronouncements, of the Notes to Condensed Consolidated Financial Statements in this quarterly report for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position and cash flows.

### Results of Operations

### Comparison of the Three Months Ended September 30, 2018 and 2017

### (In thousands)

| Revenue: | Three Months Ended September 30, 2018 | 2017 | Change |
| --- | ---: | ---: | ---: |
| Testing services revenue | $16,847 | $8,163 | $8,684 |
| Product revenue | 4,223 | 3,872 | 351 |
| License and other revenue | 114 | 156 | (42) |
| Total revenue | 21,184 | 12,191 | 8,993 |
| Operating expenses: |  |  |  |
| Cost of testing services | 5,752 | 3,156 | 2,596 |
| Cost of product | 3,135 | 2,053 | 1,082 |
| Research and development | 3,868 | 2,959 | 909 |
| Sales and marketing | 5,971 | 3,255 | 2,716 |
| General and administrative | 5,177 | 4,038 | 1,139 |
| Change in estimated fair value of contingent consideration | - | 594 | (594) |
| Total operating expenses | 23,903 | 16,055 | 7,848 |
| Loss from operations | (2,719) | (3,864) | 1,145 |
| Interest expense | (408) | (1,685) | 1,277 |
| Other expense, net | (40) | (317) | 277 |
| Change in estimated fair value of common stock warrant liability and derivative liability | (17,093) | (8,599) | (8,494) |
| Income tax benefit | 290 | 178 | 112 |
| Net loss | (19,970) | (14,287) | (5,683) |
| Net loss attributable to noncontrolling interest | — | (19) | 19 |
| Net loss attributable to CareDx, Inc. | $(19,970) | $(14,268) | $(5,702) |

39

#### Testing Services Revenue

Testing services revenue increased by $8.7 million, or 106%, for the three months ended September 30, 2018 as compared to the same period in 2017. This increase is mainly due to the 3,708 AlloSure test results provided in the three months ended September 30, 2018, following the launch of AlloSure in October 2017. Additionally, AlloMap test results increased to 4,080 in the three months ended September 30, 2018, compared to 3,864 in the same period in 2017, and the Medicare reimbursement rate for AlloMap increased from $2,841 to $3,240 on January 1, 2018. Furthermore, in the three months ended September 30, 2018, we recognized $0.3 million testing services revenue related to payments received in excess of the $2.9 million accounts receivable adjustment recorded on January 1, 2018 upon adoption of ASC 606.

As described in Note 2 of the Condensed Consolidated Financial Statements, the adoption of ASC 606 on January 1, 2018, had a $0.3 million favorable impact on Testing Revenue for the three months ended September 30, 2018, compared to the revenue under the previous methodology prescribed by ASC Topic 605, “Revenue Recognition”, for the same period.

#### Product Revenue

Product revenue increased by $0.4 million, or 9%, for the three months ended September 30, 2018, compared to the same period in 2017. The increase was due to sales of the TruSight HLA products related to the License Agreement with Illumina, which was signed in May 2018, and increased sales of Olerup QTYPE, partially offset by decreased sales of Olerup SSP and Olerup SBT products.

#### License and Other Revenue

License, and other revenue decreased by less than $0.1 million for the three months ended September 30, 2018, compared to the same period in 2017.

#### Cost of Testing Services

Cost of testing services increased by approximately $2.6 million, or 82%, for the three months ended September 30, 2018, compared to the same period in 2017, primarily due to test results provided for AlloSure, which was launched in October 2017, and the increase in AlloMap test results compared to the same period in 2017.

#### Cost of Product

Cost of product increased by $1.1 million, or 53%, for the three months ended September 30, 2018, compared to the same period in 2017, primarily due to a change in the mix of products sold. The addition of sales of TruSight HLA products, which are purchased directly from Illumina, and the reduction in sales of Olerup SBT and Olerup SSP, which are manufactured internally, led to an increase of $0.6 million. Furthermore, in the three months ended September 30, 2018, the total cost of product manufactured internally increased by $0.2 million due to higher personnel costs and by $0.2 million due to an increase in the obsolescence provision.

#### Research and Development

Research and development expenses increased by $0.9 million, or 31%, for the three months ended September 30, 2018, compared to the same period in 2017, due to an increase in stock-based compensation expense of $0.6 million and an increase in clinical trial expenses of $0.2 million.

#### Sales and Marketing

Sales and marketing expenses increased by approximately $2.7 million, or 83%, for the three months ended September 30, 2018, compared to the same period in 2017, primarily due to higher personnel related costs of $1.0 million, higher conference fees and travel costs associated with several key transplant industry events of $1.0 million, increased stock-based compensation expense of $0.2 million, and an increase in consulting fees of $0.2 million.

#### General and Administrative

General and administrative expenses increased by $1.1 million, or 28%, for the three months ended September 30, 2018, compared to the same period in 2017. This increase was primarily due to an increase of $0.7 million in personnel related expenses, increased stock-based compensation of $0.5 million, partially offset by lower consulting, legal and professional fees of $0.2 million.

#### Change in Estimated Fair Value of Contingent Consideration

In accordance with the IMX acquisition agreement, we estimated the contingent consideration liability fair value at each period end based on our common stock price at the end of the period and a probability of meeting the contractual milestone related to the number of commercial AlloSure tests performed by June 2020. The contingent consideration liability was settled in the three months ended June 30, 2018, with the achievement of the contractual milestone of 2,500 commercial AlloSure tests. Changes in the fair value of the contingent liability were nil and $0.6 million expense for the three months ended September 30, 2018 and 2017, respectively. The $0.6 million expense reflected an increase in our share price in the three months ended September 30, 2017 and an increase in our estimate of the probability of meeting the milestone under our business combination agreement with IMX.

#### Interest Expense

Interest expense decreased by $1.3 million for the three months ended September 30, 2018, compared to the same period in 2017. The interest expense of $0.4 million in the three months ended September 30, 2018, primarily consisted of interest expense and debt amortization recorded in relation to the Perceptive Credit Agreement entered into on April 17, 2018.

The interest expense of $1.7 million in the three months ended September 30, 2017, consisted of $1.3 million of interest expense and debt discount amortization related to the JGB Debt, $0.1 million of interest expense recorded in relation to deferred purchase consideration owed to the former shareholders of Allenex and $0.2 million in interest expense recorded in relation to the Allenex Notes, the Danske Bank Term Loan and the SSP Primers Loan.

The JGB Debt was entered into on March 15, 2017 and during the three months ended March 31, 2018 was converted into shares of our common stock. The deferred purchase consideration was related to the acquisition of Allenex and was settled in November 2017. The SSP Primers Loan was repaid in February 2018 and the Allenex Notes and Danske Bank Term Loan were repaid in April 2018.

#### Other Expense, Net

Other expense decreased by $0.3 million in the three months ended September 30, 2018 compared to the same period in 2017. Other expense was less than $0.1 million in the three months ended September 30, 2018. For the three months ended September 30, 2017, other expense primarily consisted of foreign exchange losses of $0.3 million.

#### Change in Estimated Fair Value of Common Stock Warrant Liability and Derivative Liability

The change in estimated fair value of common stock warrant liability and derivative liability was $17.1 million expense in the three months ended September 30, 2018 and $8.6 million expense in the comparative period in 2017.

The $17.1 million expense in the three months ended September 30, 2018 consisted of changes in liabilities for warrants exercised during the period and a charge for warrants that remained outstanding at September 30, 2018. In the three months ended September 30, 2018, approximately 1.2 million warrants with an average exercise price of $3.54 per share and a June 30, 2018 estimated fair market value of $10.14 per share were exercised. The average price of our common stock at exercise was $22.27 per share, resulting in a charge of $10.2 million. The remaining 0.4 million warrants classified as common stock warrant liability at September 30, 2018 were revalued, resulting in a remeasurement charge of $6.9 million.

The $8.6 million expense in the three months ended September 30, 2017, consisted of a remeasurement charge of $8.2 million related to the changes in fair value of common stock warrant liability and a $0.4 million charge for the change in fair value of the JGB embedded derivative. The $8.2 million expense related to our common stock warrant liability was due to (i) changes in the valuation of warrants due to the change in the share price of our common stock during the period, (ii) the adjustment in the exercise price of the warrants issued in connection with a private placement transaction completed on April 14, 2016 from $4.00 and $3.99 per share, respectively, to $1.12 per share, effective July 3, 2017, as a result of the issuance of 1,022,544 shares at a price of $1.12 pursuant to amendments to the Conditional Share Purchase Agreements we entered into with each of Midroc Invest AB, FastPartner AB, and Xenella Holding AB, the former majority shareholders of Allenex, in connection with the acquisition of Allenex, or the Conditional Share Purchase Agreements, and (iii) adjustments to the quantity and exercise price of the common stock warrants issued in connection with the JGB Debt as a result of the issuance of 1,022,544 shares at a price of $1.12 pursuant to the amendments to the Conditional Share Purchase Agreements.

As of January 1, 2018, we adopted the new accounting standard and reclassified the outstanding common stock warrant issued in connection with the JGB Debt to equity. This warrant was not re-measured through earnings after January 1, 2018. The common stock warrant issued in connection with the JGB Debt was exercised in August 2018. The Perceptive Tranche A Warrant, issued on April 17, 2018, by us in accordance with the Perceptive Credit Agreement, was also classified as equity and excluded from quarterly remeasurement. Warrants issued in connection with a private placement transaction completed on April 14, 2016, continue to be classified as liability and will be re-measured at the end of each reporting period until expired or exercised. Changes in the common stock fair value, estimated volatility and expected contractual term will significantly impact the fair value of the warrant liability.

#### Income Tax Benefit

For the three months ended September 30, 2018, we recorded an income tax benefit of $0.3 million on a loss before income taxes of $20.3 million. This benefit primarily resulted from the expectation that amortization of the various intangible assets acquired, when completed and placed in service, is not expected to be deductible for tax purposes. Accordingly, a deferred tax liability was recorded at the acquisition date for the difference between the financial reporting and tax basis of the intangibles. The effective tax rate for the nine months ended September 30, 2018 differs from the federal statutory tax rate as a result of the income tax expense and benefit related to the earnings taxed in foreign jurisdictions and the amortization of the acquired intangibles.

### Comparison of the Nine Months Ended September 30, 2018 and 2017

### (In thousands)

| Revenue: | Nine Months Ended September 30, 2018 | 2017 | Change |
| --- | ---: | ---: | ---: |
| Testing services revenue | $41,448 | $24,485 | $16,963 |
| Product revenue | 11,080 | 10,916 | 164 |
| License and other revenue | 532 | 420 | 112 |
| Total revenue | 53,060 | 35,821 | 17,239 |
| Operating expenses: |  |  |  |
| Cost of testing services | 14,432 | 9,224 | 5,208 |
| Cost of product | 8,046 | 6,558 | 1,488 |
| Research and development | 10,732 | 9,360 | 1,372 |
| Sales and marketing | 15,916 | 9,747 | 6,169 |
| General and administrative | 16,080 | 14,672 | 1,408 |
| Goodwill Impairment | — | 1,958 | (1,958) |
| Change in estimated fair value of contingent consideration | 1,017 | 309 | 708 |
| Total operating expenses | 66,223 | 51,828 | 14,395 |
| Loss from operations | (13,163) | (16,007) | 2,844 |
| Interest expense | (3,527) | (4,166) | 639 |
| Other expense, net | (2,891) | (1,191) | (1,700) |
| Change in estimated fair value of common stock warrant liability and derivative liability | (24,540) | (3,404) | (21,136) |
| Income tax benefit | 1,095 | 837 | 258 |
| Net loss | (43,026) | (23,931) | (19,095) |
| Net loss attributable to noncontrolling interest | (25) | (133) | 108 |
| Net loss attributable to CareDx, Inc. | $(43,001) | $(23,798) | $(19,203) |

#### Testing Services Revenue

Testing services revenue increased by $17.0 million, or 69%, for the nine months ended September 30, 2018, compared to the same period in 2017. This increase is mainly due to the 7,059 AlloSure test results provided in the nine months ended September 30, 2018, following the launch of AlloSure in October 2017. Additionally, AlloMap test results increased to 12,059 in the nine months ended September 30, 2018, compared to 11,475 in the same period in 2017, and the Medicare reimbursement rate for AlloMap increased from $2,841 to $3,240 on January 1, 2018. Furthermore, in the nine months ended September 30, 2018, we recognized $0.3 million testing services revenue related to payments received in excess of the $2.9 million accounts receivable adjustment recorded on January 1, 2018 upon adoption of ASC 606.

As described in Note 2 of the Condensed Consolidated Financial Statements, the adoption of ASC 606 on January 1, 2018, had a $0.8 million favorable impact on Testing Revenue for the nine months ended September 30, 2018, compared to the revenue under the previous methodology prescribed by ASC Topic 605, “Revenue Recognition”, for the same period.

#### Product Revenue

Product revenue increased by $0.2 million, or 2%, for the nine months ended September 30, 2018, compared to the same period in 2017. The increase was due to sales of the TruSight HLA products related to the License Agreement with Illumina, which was signed in May 2018, and increased sales of Olerup QTYPE, partially offset by a decrease in sales of Olerup SSP and Olerup SBT products.

#### License and Other Revenue

License and other revenue increased by $0.1 million for the nine months ended September 30, 2018, which is primarily due to revenue earned from Illumina under our the License Agreement.

#### Cost of Testing

Cost of testing increased by approximately $5.2 million, or 56%, for the nine months ended September 30, 2018, compared to the same period in 2017, primarily due to the test results provided for AlloSure, which was launched in October 2017.

#### Cost of Product

Cost of product increased by $1.5 million, or 23%, for the nine months ended September 30, 2018, compared to the same period in 2017, primarily due to a change in the mix of products sold and increase in obsolescence provision. The addition of sales of TruSight HLA products, which are purchased directly from Illumina, and the reduction in sales of Olerup SBT and Olerup SSP, which are manufactured internally, led to an increase of $0.6 million. Furthermore, in the nine months ended September 30, 2018, the total cost of product manufactured internally increased by $0.2 million due to higher personnel costs and by $0.6 million due to an increase in the obsolescence provision.

#### Research and Development

Research and development expenses increased by $1.4 million, or 15%, for the nine months ended September 30, 2018, compared to the same period in 2017. This increase reflects an increase of $1.1 million in stock-based compensation expense and an increase of $0.5 million in clinical trial costs, partially offset by lower personnel costs of $0.3 million.

#### Sales and Marketing

Sales and marketing expenses increased by approximately $6.2 million, or 63%, for the nine months ended September 30, 2018, compared to the same period in 2017, primarily due to an increase in personnel related expenses of $2.5 million, higher conference fees and travel costs of $2.1 million associated with several key transplant industry events, increased stock-based compensation expenses of $0.6 million, higher facilities and software related costs of $0.7 million and higher consulting fees of $0.2 million.

#### General and Administrative

General and administrative expenses increased by $1.4 million, or 10%, for the nine months ended September 30, 2018, compared to the same period in 2017. This increase primarily reflects an increase of $1.8 million in stock-based compensation expense and an increase of $1.0 million in personnel related expenses, partially offset by a decrease in consulting and professional fees of $1.4 million.

#### Goodwill Impairment

In the three months ended March 31, 2017, we determined that the decrease in our market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017. We recorded a goodwill impairment charge of $2.0 million and wrote off the remaining goodwill in the Post-Transplant reporting unit as of March 31, 2017. No impairment was identified in the nine months ended September 30, 2018.

#### Change in Estimated Fair Value of Contingent Consideration

In accordance with the IMX acquisition agreement, we estimated the contingent consideration liability fair value at each period end based on our common stock price at the end of the period and a probability of meeting the contractual milestone related to the number of commercial tests performed by June 2020. The contingent consideration liability was settled in the six months ended June 30, 2018, with the achievement of the contractual milestone of 2,500 commercial AlloSure tests. Changes in fair value of the contingent liability were $1.0 million expense compared to $0.3 million expense for the nine months ended September 30, 2018 and 2017 respectively. The $1.0 million expense reflected an increase in our share price from January 1, 2018 to the date of the issuance of the 227,845 shares and the settlement of the liability. The $0.3 million expense reflected an increase in our share price in the nine months ended September 30, 2017 and an increase in our estimate of the probability of meeting the milestone under our business combination agreement with IMX.

#### Interest Expense

Interest expense decreased by $0.6 million for the nine months ended September 30, 2018, compared to the same period in 2017.

The interest expense of $3.5 million in the nine months ended September 30, 2018, consisted of $2.4 million of interest expense and debt discount amortization related to the JGB Debt, $0.9 million of interest expense and debt amortization recorded in relation to the

Perceptive Credit Agreement entered into on April 17, 2018 and $0.2 million of interest expense recorded in relation to the Allenex Notes, the Danske Bank Term Loan and the SSP Primers Loan.

The interest expense of $4.2 million in the nine months ended September 30, 2017, consisted of $2.8 million of interest expense and debt discount amortization related to the JGB Debt, $0.5 million of interest expense recorded in relation to deferred purchase consideration owed to the former shareholders of Allenex, $0.6 million in interest expense recorded on the Allenex Notes, the Danske Bank Term Loan and the SSP Primers Loan and $0.1 million of interest expense recorded on the East West Bank Debt.

The JGB Debt was entered into on March 15, 2017 and during the three months ended March 31, 2018 was converted into shares of our common stock. The deferred purchase consideration was related to the acquisition of Allenex and was settled in November 2017. The SSP Primers Loan was repaid in February 2018 and the Allenex Notes and Danske Bank Term Loan were repaid in April 2018. The outstanding indebtedness under the loan agreement with East West Bank was repaid in March 2017.

#### Other Expense, Net

Other expense increased by $1.7 million in the nine months ended September 30, 2018 compared to the same period in 2017. In the nine months ended September 30, 2018, the other expense charge primarily consisted of a loss of $2.8 million for the conversion of the JGB Debt in the three months ended March 31, 2018. In the nine months ended September 30, 2017, the other expense charge consisted of a foreign exchange loss of $0.8 million, $0.3 million loss on early extinguishment of existing indebtedness under the Loan Agreement with East West Bank and a $0.1 million transaction settlement fee.

#### Change in Estimated Fair Value of Common Stock Warrant Liability and Derivative Liability

The change in estimated fair value of common stock warrant liability and derivative liability was $24.5 million expense in the nine months ended September 30, 2018 and $3.4 million expense in the comparative period in 2017.

The $24.5 million expense in the nine months ended September 30, 2018, consisted of a remeasurement charge of $27.1 million related to the changes in fair value of common stock warrant liability, partially offset by a $2.6 million gain recorded for the changes in fair value of the JGB Debt embedded derivative between January 1, 2018 and the conversion date of March 27, 2018.

The $27.1 million remeasurement charge in the nine months ended September 30, 2018 related to changes in the fair value of common stock warrant liability and consisted of a charge for warrants exercised during the period and for warrants that remained outstanding at September 30, 2018. In the nine months ended September 30, 2018, approximately 1.7 million warrants with an average exercise price of $2.86 per share and a December 31, 2017 fair market value of $5.70 per share were exercised. The average price of our common stock on the days of exercise was $19.53 per share, resulting in a charge of $18.2 million. The remaining 0.4 million warrants classified as common stock warrant liability at September 30, 2018 were revalued, resulting in a remeasurement charge of $8.9 million.

In the nine months ended September 30, 2017, the $3.4 million charge reflected $4.3 million expense related to our common stock warrant liability and $0.9 million income related to our derivative liability. The $4.3 million expense was primarily caused by the effect of the increase in our stock price on the mark-to-market valuations. The JGB Debt included certain embedded derivatives that required bifurcation. The value of these derivatives declined $0.9 million from the initial valuation on March 15, 2017 to September 30, 2017.

As of January 1, 2018, we adopted the new accounting standard and reclassified the outstanding common stock warrant issued in connection with the JGB Debt to equity. This warrant was not re-measured through earnings after January 1, 2018. This common stock warrant issued in connection with the JGB Debt was exercised in August 2018. The Perceptive Tranche A Warrant, issued on April 17, 2018, by us in accordance with the Perceptive Credit Agreement, was also classified as equity and excluded from quarterly remeasurement. Warrants issued in connection with a Private Placement transaction completed on April 14, 2016, continue to be classified as liability and will be re-measured at the end of each reporting period until expired or exercised. Changes in the common stock fair value, estimated volatility and expected contractual term will significantly impact the fair value of the warrant liability.

#### Income Tax Benefit

For the nine months ended September 30, 2018, we recorded an income tax benefit of $1.1 million on a loss before income taxes of $44.1 million. This benefit primarily resulted from the expectation that amortization of the various intangible assets acquired, when completed and placed in service, is not expected to be deductible for tax purposes. Accordingly, a deferred tax liability was recorded at the acquisition date for the difference between the financial reporting and tax basis of the intangibles. The effective tax rate for the nine months ended September 30, 2018 differs from the federal statutory tax rate as a result of the income tax expense and benefit related to the earnings taxed in foreign jurisdictions and the amortization of the acquired intangibles.

### Cash Flows for the Nine Months Ended September 30, 2018 and 2017

The following table summarizes the primary sources and uses of cash for the periods presented:

*(in thousands)*

| Net cash (used in) provided by: | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: |
| Operating activities | $(6,005) | $(12,157) |
| Investing activities | (6,969) | (1,069) |
| Financing activities | 12,956 | 11,459 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (62) | (104) |
| Net decrease in cash, cash equivalents and restricted cash | $(80) | $(1,871) |

#### Operating Activities

Net cash used in operating activities consists of net loss, adjusted for certain noncash items in the statement of operations and changes in operating assets and liabilities. Cash used in operating activities for the nine months ended September 30, 2018 was $6.0 million. Our net loss of $43.0 million was our primary use of cash in operating activities and included a number of noncash items. Our noncash items included a $24.5 million loss on the revaluation of common stock warrant and derivative liabilities to estimated fair value, a $5.1 million stock-based compensation expense, $3.0 million of depreciation and amortization expense, $2.8 million loss on the conversion of debt to shares of our common stock, $2.2 million amortization expense related to the JGB Debt discount, $1.0 million contingent consideration revaluation expense and $0.2 million of amortization expense of inventory on fair market value adjustment. Net operating assets decreased by $1.8 million.

Cash used in operating activities for the nine months ended September 30, 2017 was $12.2 million. Our net loss of $24.0 million was our primary use of cash in operating activities; which also included a number of noncash items. Our noncash items included a $3.4 million loss on revaluation of warrants and derivative liabilities to estimated fair value, a $2.0 million of goodwill impairment related to our purchase of Allenex, $2.7 million of depreciation and amortization, $2.8 million of amortization of debt discount and noncash interest expense, $1.3 million of stock-based compensation expense, $0.3 million contingent consideration revaluation expense and $0.3 million of amortization expense of inventory on fair market value adjustment. Net operating assets decreased $1.0 million.

#### Investing Activities

For the nine months ended September 30, 2018, net cash used in investing activities was $7.0 million and consisted of $5.2 million related to the acquisition of intangible assets per the Illumina License Agreement, $1.1 million for purchases of property and equipment and $0.7 million for the acquisition of the Allenex minority interest.

For the nine months ended September 30, 2017, net cash used in investing activities was $1.1 million, and consisted of $0.5 million for the acquisition of Allenex, $0.5 million for the acquisition of the Conexio business assets and $0.1 million purchases of property and equipment.

#### Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2018 of $13.0 million was primarily related to the $14.3 million net proceeds from the Perceptive Credit Agreement, cash proceeds of $11.0 million from the exercise of warrants, and $0.6 million cash proceeds from the exercise of stock options, partially offset by $11.4 million of principal payments of the promissory notes issued to FastPartner AB and Mohammed Al Amoudi, Danske Term Loan, and the SSP Primers Loan, $0.7 million of repurchase of common stock under employee incentive plans, $0.7 million repayment of the Danske Credit Facility, and $0.2 million of acquisition of Conexio Genomics Pty Ltd.

Net cash provided by financing activities for the nine months ended September 30, 2017 of $11.5 million consisted primarily of $24.0 million in net proceeds received from the JGB Debt agreement in March 2017 and a $0.6 million increase in the Danske Credit Facility, partially offset by $13.3 million of principal payments on debt and capital lease obligations.

### Liquidity and Capital Resources

We have incurred significant losses and negative cash flows from operations since our inception and had an accumulated deficit of $308.1 million at September 30, 2018. As of September 30, 2018, we had cash and cash equivalents of $26.2 million, and $13.4 million of debt, net of debt discount, outstanding under our long-term debt obligations.

We may require additional financing in the future to fund working capital and pay our obligations as they come due. Additional financing might include one or more common stock offerings, debt, cash from collaboration agreements or a combination of these. However, there can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. We believe our existing cash balance and expected revenues will be sufficient to meet our anticipated cash requirements for at least the next 12 months.

#### Perceptive Credit Agreement

On April 17, 2018, we entered into a credit agreement with Perceptive for a term loan of $15.0 million and repaid the outstanding indebtedness under the Allenex Notes, and the Danske Term Loan and Credit Facility. A second tranche of $10.0 million will be available at our option subject to the satisfaction of customary conditions.

#### Allenex Notes, Danske Term Loan and Danske Credit Facility

All outstanding amounts under the Allenex Notes of $4.4 million and Danske Term Loan and Credit Facility of $6.7 million were repaid on April 17, 2018.

#### JGB Debt

On March 1, 2018, we notified JGB of our intent to prepay on April 13, 2018, in full the outstanding principal and interest under the JGB Debentures. During the three months ended, March 31, 2018, JGB converted all outstanding $26.7 million of principal and accrued interest of the JGB Debt into an aggregate of 6,161,331 shares of our common stock. Restricted cash of $9.4 million was released from any restrictions after the conversion and included in our cash and cash equivalent balance as of March 31, 2018.

### Factors Affecting Our Performance

#### The Number of AlloMap and AlloSure Tests We Receive and Report

The growth of our testing services revenue is tied to the number of AlloMap and AlloSure tests we receive and report. Historically, less than two percent of AlloMap tests received are not reported due to improper sampling, damage in transit or other causes. We incur costs in connection with collecting and shipping all samples and a portion of the costs when we cannot ultimately issue a test report. As a result, the number of samples received largely correlates directly to the number of test reports.

#### The Number of Diagnostic Products We Sell

The growth of our product revenues is tied to the sales of the Olerup SSP, Olerup QTYPE, Olerup SBT and TruSight HLA product lines. The product sales organizations are located in Stockholm, Sweden; Vienna, Austria; Fremantle, Australia and West Chester, Pennsylvania. Products are sold directly to customers in 14 countries. We also use distributors to sell products in approximately 60 countries.

#### Continued Adoption of and Reimbursement for AlloMap

AlloMap test volume and the corresponding reimbursement revenue has generally increased over time since the launch of AlloMap, as Medicare provided reimbursement and payers adopt coverage policies and fewer payers consider AlloMap to be experimental and investigational. The rate at which our tests are covered and reimbursed has, and is expected to continue to vary by payer. Revenue growth depends on our ability to maintain Medicare reimbursement, achieve broader reimbursement from third party payers and to expand the number of tests per patient and the base of healthcare providers.

On June 10, 2016, Centers for Medicare & Medicaid Services, or CMS, announced proposed changes in reimbursement for a number of established molecular diagnostic tests, including AlloMap. Under the gapfill reimbursement rate for 2017, AlloMap reimbursement for patients covered by Medicare would have been reduced from $2,821 to $1,921, effective January 1, 2017. This reimbursement rate, determined by gapfill submissions from the Medicare contractors, was open to reconsideration until October 31, 2016. We submitted a request for reconsideration of the reimbursement rate determined by the Medicare contractors and in November 2016 CMS released the final 2017 Clinical Laboratory Fee Schedule reflecting the rate of reimbursement at $2,841 for AlloMap.

The Protecting Access to Medicare Act of 2014, or PAMA, includes a substantial new payment system for clinical laboratory tests under the CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenues from payments made under the

CLFS would report initially and then on a subsequent three-year basis thereafter (or annually for advanced diagnostic laboratory tests, or ADLTs), private payer payment rates and volumes for their tests. The final PAMA ruling was issued June 17, 2016 indicating that data for reporting for the new PAMA process would begin in 2017 and the new market based rates took effect on January 1, 2018. Effective January 1, 2018, Medicare plans to reimburse us $3,240 for AlloMap testing of Medicare beneficiaries, which represents a 14% increase over the 2017 reimbursement rate. AlloMap has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers, including Aetna, Anthem, Cigna, Health Care Services Corporation (HCSC), Humana, Kaiser Foundation Health Plan, Inc., and TRICARE.

#### Reimbursement for AlloSure

On September 26, 2017 we received notice that the Molecular Diagnostics Services, or MolDX, Program developed by Palmetto GBA has set AlloSure reimbursement at $2,841. Effective October 9, 2017, AlloSure was made available for commercial testing with Medicare coverage and reimbursement. We believe the use of AlloSure, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a kidney transplant. In particular, we believe AlloSure can improve patient care by helping healthcare providers to reduce the use of invasive biopsies and determine the appropriate dosage levels of immunosuppressants.

#### Development of Additional Products and Services

We rely on sales of AlloMap, AlloSure, Olerup SSP, Olerup SBT, Olerup QTYPE and TruSight HLA to generate the majority of our revenue. Our development pipeline includes other transplant diagnostic solutions to help clinicians and transplant centers make personalized treatment decisions throughout a transplant patient’s lifetime. We expect to invest in research and development in order to develop additional products. Our success in developing new products and services will be important in our efforts to grow our business by expanding the potential market for our products and diversifying our sources of revenue.

#### Timing of Research and Development Expenses

Our spending on experiments may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new products, as well as on-going clinical and outcome studies to further the published evidence to support our commercialized AlloMap and AlloSure tests. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.

### Contractual Obligations

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.

### Off-Balance Sheet Arrangements

As of September 30, 2018, we had no off-balance sheet arrangements as defined under Regulation S-K 303(a)(4) of the Exchange Act, and the instructions thereto.

### JOBS Act Accounting Election

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

### Foreign Operations

The accompanying condensed consolidated balance sheets contain certain recorded assets in foreign countries, namely Stockholm, Sweden, Vienna, Austria and Fremantle, Australia. Although these countries are considered economically stable and we have experienced no notable burden from foreign exchange transactions, export duties or government regulations, unanticipated events in foreign countries could have a material adverse effect on our operations.

## Market risk

As filed, 2,203 characters.

#### Interest Rate Risk

We are exposed to market risks in the ordinary course of our business. We had cash and cash equivalents of $26.2 million and $16.9 million at September 30, 2018 and December 31, 2017, respectively, which consisted of bank deposits and money market funds. Additionally, we had debt of $13.4 million and $34.1 million as of September 30, 2018 and December 31, 2017, respectively. Such variable interest-bearing instruments carry a degree of risk. However, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. A hypothetical fifty basis point increase or decrease in interest rates would have a less than $0.1 million impact on our unaudited condensed consolidated financial statements.

#### Foreign Currency Exchange Risk

We have operations in Sweden, Austria, Australia and sell to other countries throughout the world. As a result, we are subject to significant foreign currency risks, including transacting in foreign currencies, investment in a foreign entity, as well as assets and debts denominated in foreign currencies. Our testing services revenue is primarily denominated in U.S. dollars. Our product revenue is denominated primarily in Swedish Krona, the Euro, the Australian dollar and U.S. dollars. Consequently, our revenue denominated in foreign currency is subject to foreign currency exchange risk. A portion of our operating expenses are incurred outside of the U.S. and are denominated in Swedish Krona, the Euro, and the Australian Dollar, which are also subject to fluctuations due to changes in foreign currency exchange rates. An unfavorable 10% change in foreign currency exchange rates for our assets and liabilities denominated in foreign currencies at September 30, 2018, would have negatively impacted our financial results for the nine months ended September 30, 2018 by $0.2 million and our product revenue by $0.5 million. Currently, we do not have any near-term plans to enter into a formal hedging program to mitigate the effects of foreign currency volatility. We will continue to reassess our approach to managing our risk relating to fluctuations in foreign currency exchange rates.

## Controls and procedures

As filed, 1,960 characters.

### Evaluation of Disclosure Controls and Procedures

Management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(b) and 15d-15(e) promulgated under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that we are required to apply our judgment in evaluating the benefits of possible controls and procedures relative to our costs. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective at the reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed in the reports we file and submit under the Exchange Act, is (i) recorded, processed, summarized and reported as and when required and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the nine months ended September 30, 2018 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 8,124 characters.

Our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 22, 2018, Part I –Item 1A, Risk Factors, describes important risk factors that could cause our business, financial condition, results of operations and growth prospects to differ materially from those indicated or suggested by forward-looking statements made in this Quarterly Report on Form 10-Q or presented elsewhere by management from time to time. There have been no material changes in the risk factors that appear in Part I - Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 22, 2018 other than those listed below and that the risk factor with the heading “As a result of our failure to timely file our Annual Report on Form 10-K for the year ended December 31, 2016 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, we are currently ineligible to file new short form registration statements on Form S-3, and we are unable to access our existing Registration Statement on Form S-3 for sales of securities by us, which may impair our ability to raise capital on terms favorable to us, in a timely manner or at all.” is no longer applicable to us as we regained eligibility to file new short form registration statements on Form S-3 on June 1, 2018 and we filed a universal shelf registration statement on Form S-3 (File No 333-227168) on August 31, 2018, which was declared effective by the SEC on October 11, 2018. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business.

***Our credit agreement contains restrictive and financial covenants that may limit our operating flexibility.***

Our credit agreement with Perceptive contains certain restrictive covenants that limit our ability to merge with other companies or consummate certain changes of control, acquire other companies, make certain investments or acquisitions, pay dividends, transfer or dispose of assets, amend certain material agreements, incur additional indebtedness, permit additional liens or enter into various specified transactions. We therefore may not be able to engage in any of the foregoing transactions unless we obtain the consent of the lender or terminate our existing debt agreement. There is no guarantee that we will be able to generate sufficient cash flow or sales to pay the principal and interest under our debt agreement.

Refer to Note 10 of the notes to the unaudited condensed consolidated financial statements included in Part I, Item I of this Quarterly Report on Form 10-Q for details on our credit agreement with Perceptive.

***Our License and Commercialization Agreement with Illumina may not result in material benefits to our business.***

Pursuant to our License and Commercialization Agreement with Illumina, we acquired the worldwide distribution, development and commercialization rights to Illumina, Inc.’s next generation sequencing product line for use in the field of transplantation.

Under the License Agreement, we are obligated to complete timely development and commercialization of future products, including meeting certain commercialization milestones. The failure to meet any such milestones could result in the loss of exclusivity for the affected licensed products. Additionally, we agreed to minimum purchase commitments of finished products and raw materials from Illumina through 2023 and we are required to pay royalties in the mid-single to low-double digits on sales of future commercialized products.

We cannot make any assurances that our efforts under the License Agreement will be successful. As a result, we may not be able to fully realize the anticipated strategic benefits of the License Agreement. If we fail to successfully execute on the License Agreement, we may not realize the benefits expected from the transaction and our business may be harmed.

**We do not expect to pay dividends in the foreseeable future. As a result, you must rely on stock appreciation for any return on your investment.**

We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will also depend on our financial condition, results of operations, capital requirements and other factors and will be at the discretion of our board of directors. Accordingly, you will have to rely on capital appreciation, if any, to earn a return on your investment in our common stock. Furthermore, debt agreement with Perceptive prohibits us from paying dividends without the Perceptive’s prior consent, and we may in the future become subject to additional contractual restrictions on, or prohibitions against, the payment of dividends.

**If we are unable to raise additional capital on acceptable terms in the future, it may limit our ability to develop and commercialize new diagnostic solutions and technologies, and we may have to curtail or cease operations.**

We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure, commercial operations and research and development activities. Specifically, we may need to raise additional capital to, among other things:

- develop other solutions for clinical surveillance in transplantation;
- increase our selling and marketing efforts to drive market adoption and address competitive developments;
- expand our clinical laboratory operations;
- fund our clinical validation study activities;
- expand our research and development activities;
- sustain or achieve broader commercialization of AlloMap, AlloSure and our pre-transplant tests or enhancements to those tests;
- acquire or license products or technologies including through acquisitions; and
- finance our capital expenditures and general and administrative expenses.

Our present and future funding requirements will depend on many factors, including:

- the level of research and development investment required to develop our new solutions ;
- costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;
- our need or decision to acquire or license complementary technologies or acquire complementary businesses;
- changes in test development plans needed to address any difficulties in commercialization;
- competing technological and market developments;
- whether our diagnostic solutions become subject to additional FDA or other regulation; and
- changes in regulatory policies or laws that affect our operations.

Additional capital, if needed, may not be available on satisfactory terms, or at all. Furthermore, if we raise additional funds by issuing equity securities, dilution to our existing stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. For example, we have the ability to sell up to $50.0 million of additional shares of our common stock to the public through an “at the market” offering pursuant to the Sales Agreement we entered into with Jefferies, LLC on August 31, 2018. Any shares of common stock issued in the at-the-market offering will result in dilution to the existing stockholders. If we raise additional funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of holders of our common stock, and the terms of the debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or our solutions under development, or grant licenses on terms that are not favorable to us, which could lower the economic value of those programs to us. If adequate funds are not available, we may have to scale back our operations or limit our research and development activities, which may cause us to grow at a slower pace, or not at all, and our business could be adversely affected.

Filed Nov 8, 2018.
Source: SEC EDGAR, the filing index for accession 0001564590-18-028612. Last ingested by Listed: Nov 13, 2026, 16:18 ET. No prices; not investment advice.
